Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug;42(1):52-62.
doi: 10.1007/s12020-012-9696-x. Epub 2012 May 13.

Skeletal and extraskeletal actions of denosumab

Kathrin Sinningen  1 , Elena Tsourdi, Martina Rauner, Tilman D Rachner, Christine Hamann, Lorenz C Hofbauer
Affiliations
Review

Skeletal and extraskeletal actions of denosumab

Kathrin Sinningen et al. Endocrine. 2012 Aug.

Abstract

Osteoclasts and osteoblasts define skeletal mass, structure and strength through their respective actions in resorbing and forming bone. This remodeling process is orchestrated by the actions of hormones and growth factors, which regulate a cytokine system comprising the receptor activator of nuclear factor κB ligand (RANKL), its receptor RANK and the soluble decoy receptor osteoprotegerin (OPG). Bone resorption depends on RANKL, which determines osteoclast formation, activity and survival. Importantly, cells of the osteoblastic lineage mainly provide RANKL and therefore, are central in the regulation of osteoclast functions. Catabolic effects of RANKL are inhibited by OPG, a TNF receptor family member that binds RANKL, thereby preventing the activation of its receptor RANK, which is expressed by osteoclast precursors. Because this cytokine network is pivotal for the regulation of bone mass in health and diseases, including osteoporosis, rheumatoid arthritis and malignant bone conditions, it has been successfully used for the generation of a targeted therapy to block osteoclast actions. The clinical approval of denosumab, a fully monoclonal antibody against RANKL, provides a novel option to treat bone diseases with a potent, targeted and reversible inhibitor of bone resorption. Although RANKL is also expressed by endothelial cells, T lymphocytes, synovial fibroblasts and various tumor cells, no meaningful clinical extraskeletal effects have been reported after administration of denosumab. This article summarizes the molecular and cellular basis of the RANKL/RANK/OPG system and presents preclinical and clinical studies on the skeletal actions of denosumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S39-45 - PubMed
    1. J Exp Med. 2000 Aug 21;192(4):463-74 - PubMed
    1. J Clin Endocrinol Metab. 2000 Jul;85(7):2355-63 - PubMed
    1. Bone. 2009 Oct;45(4):669-76 - PubMed
    1. Arthritis Rheum. 2000 Apr;43(4):821-6 - PubMed

MeSH terms

LinkOut - more resources